Sorafenib for hepatocellular carcinoma patients beyond Milan criteria after orthotopic liver transplantation: A case control study

World Journal of Surgical Oncology

Volumn 10, Issue , 2012, Pages

  Teng, Chieh Lin ^a,b,c   Hwang, Wen Li ^a   Chen, Yi Ju ^a   Chang, Kuang Hsi ^a   Cheng, Shao Bin ^a,c  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b TUNGHAI UNIVERSITY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Adjuvant therapy; HCC; OLT; Sorafenib

Indexed keywords

METHYLPREDNISOLONE; RAPAMYCIN; SORAFENIB; TACROLIMUS; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CASE CONTROL STUDY; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; RETROSPECTIVE STUDY; UNSPECIFIED SIDE EFFECT; ADJUVANT CHEMOTHERAPY; ANALYSIS OF VARIANCE; CHINA; HEALTH SURVEY; KAPLAN MEIER METHOD; LIVER TUMOR; METHODOLOGY; MIDDLE AGED; MORTALITY; STATISTICS; TIME;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; CHINA; FEMALE; HEALTH STATUS INDICATORS; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PYRIDINES; RETROSPECTIVE STUDIES; STATISTICS AS TOPIC; TIME FACTORS;

EID: 84862810116     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-10-41     Document Type: Article

References (17)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003, 362:1907-1917. 10.1016/S0140-6736(03)14964-1, 14667750.
2. Cabrera R, Nelson DR. Review article: the management of hepatocellular carcinoma. Alimentary pharmacology & therapeutics 2010, 31:461-476. 10.1111/j.1365-2036.2009.04200.x, 22257079.
3. Merican I, Guan R, Amarapuka D, Alexander MJ, Chutaputti A, Chien RN, Hasnian SS, Leung N, Lesmana L, Phiet PH, Sjalfoellah Noer HM, Sollano J, Sun HS, Xu DZ. Chronic hepatitis B virus infection in Asian countries. Journal of gastroenterology and hepatology 2000, 15:1356-1361. 10.1046/j.1440-1746.2000.0150121356.x, 11197043.
4. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. Journal of cancer research and clinical oncology 2004, 130:417-422.
5. Bruix J, Llovet JM. Major achievements in hepatocellular carcinoma. Lancet 2009, 373:614-616. 10.1016/S0140-6736(09)60381-0, 19231618.
6. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. The New England journal of medicine 1996, 334:693-699. 10.1056/NEJM199603143341104, 8594428.
7. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ. Design and endpoints of clinical trials in hepatocellular carcinoma. Journal of the National Cancer Institute 2008, 100:698-711. 10.1093/jnci/djn134, 18477802.
8. Guan YS, He Q. Sorafenib: activity and clinical application in patients with hepatocellular carcinoma. Expert opinion on pharmacotherapy 2011, 12:303-313. 10.1517/14656566.2011.546346, 21226640.
9. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. The New England journal of medicine 2008, 359:378-390. 10.1056/NEJMoa0708857, 18650514.
10. Fan HL, Chen TW, Hsieh CB, Jan HC, His SC, De-Chuan C, Chu CH, Yu JC. Liver transplantation is an alternative treatment of hepatocellular carcinoma beyond the Milan criteria. American journal of surgery 2010, 200:252-257. 10.1016/j.amjsurg.2009.07.049, 20122677.
11. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247. 10.1016/j.ejca.2008.10.026, 19097774.
12. Zhang Q, Chen H, Li Q, Zang Y, Chen X, Zou W, Wang L, Shen ZY. Combination adjuvant chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin after liver transplantation for hepatocellular carcinoma: a preliminary open-label study. Investigational new drugs 2011, 29:1360-1369. 10.1007/s10637-011-9726-1, 21809025.
13. Saab S, McTigue M, Finn RS, Busuttil RW. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy. Experimental and clinical transplantation: official journal of the Middle East Society for Organ Transplantation 2010, 8:307-313.
14. Kim R, El-Gazzaz G, Tan A, Elson P, Byrne M, Chang YD, Aucejo F. Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation. Oncology 2010, 79:62-66. 10.1159/000319548, 21071991.
15. Yoon DH, Ryoo BY, Ryu MH, Lee SG, Hwang S, Suh DJ, Lee HC, Kim TW, Ahn CS, Kim KH, Moon DB, Kang YK. Sorafenib for recurrent hepatocellular carcinoma after liver transplantation. Japanese journal of clinical oncology 2010, 40:768-773. 10.1093/jjco/hyq055, 20494947.
16. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003, 37:429-442. 10.1053/jhep.2003.50047, 12540794.
17. Tan WF, Qiu ZQ, Yu Y, Ran RZ, Yi B, Lau WY, Liu C, Qiu YH, Feng FL, Wang JH, Yan PN, Zhang BH, Wu MC, Luo XJ, Jiang XQ. Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation. Acta pharmacologica Sinica 2010, 31:1643-1648. 10.1038/aps.2010.124, 21102481.